The maraviroc expanded access program — safety and efficacy data from an open-label study

References

• Selzentry [package insert]. Research Triangle Park, NC: ViiV Healthcare; 2014.
   Google Scholar
• Celsentri [summary of product characteristics]. http://www.medicines.org.uk/emc/medicine/20386. Accessed May 19, 2014.
   Google Scholar
• Gulick RM, Lalezari J, Goodrich J, et al. MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429–1441.
   PubMed Web of Science ®Google Scholar
• Fätkenheuer G, Nelson M, Lazzarin A, et al. MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008;359:1442–1455.
   PubMed Web of Science ®Google Scholar
• Hardy WD, Gulick RM, Mayer H, et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr. 2010;55:558–564.
   PubMed Web of Science ®Google Scholar
• Schapiro JM, Boucher CA, Kuritzkes DR, et al. Baseline CD4+ T- cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients. Antivir Ther. 2011;16:395–404.
   PubMed Web of Science ®Google Scholar
• Clotet B, Bellos N, Molina JM, et al. POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169–1178.
   PubMed Web of Science ®Google Scholar
• Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355–365.
   PubMed Web of Science ®Google Scholar
• Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol. 2007;81:2359–2371.
   PubMed Web of Science ®Google Scholar
• Roche M, Salimi H, Duncan R, et al. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology. 2013;10:43.
   PubMed Web of Science ®Google Scholar
• Feyertag F, Xiang X, Lewis M, et al. Population dynamics of R5-tropic HIV-1 associated with maraviroc resistance. Antivir Ther. 2013;18:A34.
   Web of Science ®Google Scholar
• Swenson LC, Chui CK, Brumme CJ, et al. Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure. Antimicrob Agents Chemother. 2013;57:6122–6130.
   PubMed Web of Science ®Google Scholar
• Haubrich R, Cahn P, Grinsztejn B, et al. DUET-1: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 612 treatment-experienced HIV-1-infected patients. Poster presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3–6, 2008; Boston, MA, USA.
   Google Scholar
• Johnson MA, Campbell T, Clotet B, et al. DUET-2 study group. DUET-2: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 591 treatment-experienced HIV-1-infected patients. Poster presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3–6, 2008; Boston, MA.
   Google Scholar
• Thompson MA, Aberg JA, Cahn P, et al. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321–333.
   PubMed Web of Science ®Google Scholar
• DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. 11-3-2013; Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents; Convened by the Department of Health and Human Services (DHHS): 1–139.
   Google Scholar
• Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis. 2007;196:304–312.
   PubMed Web of Science ®Google Scholar
• Garred P, Madsen HO, Petersen J, et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol. 1998;25:1462–1465.
   PubMed Web of Science ®Google Scholar
• Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med. 2006;203:35–40.
   PubMed Web of Science ®Google Scholar
• Dean M, Jacobson LP, McFarlane G, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res. 1999;59:3561–3564.
   PubMed Web of Science ®Google Scholar
• Moreno C, Gustot T, Nicaise C, et al. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology. 2005;42:854–862.
   PubMed Web of Science ®Google Scholar
• Nichols WG, Steel HM, Bonny T, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother. 2008;52:858–865.
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Than S, Valluri SR, Heera J, Mukwaya G. Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program. HIV Clin Trials. 2012;13:83–89.
   PubMed Web of Science ®Google Scholar